Protai

Company Overview

Snapshot

Founded in July 2021 by Eran Seger and Kirill Pevzner, Protai operates with 11–50 employees. The company has raised $20 million across two funding rounds from investors including Grove Ventures and Pitango HealthTech. In May 2026, Protai was recognized as one of the Most Innovative Life Science Startups at Biomed Israel 2026.

Business overview

Protai is an AI-driven drug discovery company that has developed an end-to-end platform to comprehensively map the course of disease at the protein level. Its core technology leverages machine learning models combined with deep proteomics to identify up to 1 million proteoforms, including post-translational modifications, protein-protein interactions, quantifications, and different structural populations of proteins. The company's platform aims to enhance the observation of cellular function and improve the efficiency of new drug discovery, primarily serving the pharmaceutical and life sciences industries within the Health Tech & Life Sciences sector.

Strategic signal

In May 2026, Protai was awarded as one of the Most Innovative Life Science Startups at Biomed Israel 2026. This recognition signals strong industry validation for Protai's AI-powered drug discovery platform and its innovative approach to proteomics, indicating significant forward momentum and potential for strategic partnerships and further investment in the competitive biotech landscape.

Company Intelligence Q&A

What significant recognition did Protai receive recently?

In May 2026, Protai was awarded as one of the Most Innovative Life Science Startups at Biomed Israel 2026, highlighting its advancements in the life sciences sector.

What advancements did Protai showcase in February 2026?

In February 2026, Protai announced it would showcase its AIMS™ drug discovery platform and preclinical results for its KAT6A degrader program at global scientific conferences in spring 2026, demonstrating progress in AI-driven structural modeling and mass-spectrometry-based structural proteomics.

What strategic move did Protai make regarding its advisory board in October 2025?

In October 2025, Protai strengthened its advisory board by adding three prominent scientists: Dr. Philip Jones, Dr. Ian Churcher, and Dr. Annalisa DAndrea. This move aims to accelerate drug discovery programs and support the company's expansion into immunology and inflammation.

What was the total capital raised by Protai across its funding rounds?

Protai has raised a total of $20 million across two funding rounds. The company secured an additional $12 million in its Seed round in March 2023, following an initial $8 million Seed funding in January 2022.

Which investors participated in Protai's Seed funding rounds?

Protai's Seed funding rounds saw participation from Grove Ventures. Grove Ventures led the initial $8 million Seed round in January 2022, with both firms following on in the subsequent $12 million extension in March 2023.